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(SORARE), Toulouse, France
Correspondence and offprint requests to: Joost P. Schanstra; E-mail: joost-peter.schanstra@inserm.fr and Stéphane Decramer;
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ABSTRACT
Background. Posterior urethral valves (PUV) account for 17% of paediatric end-stage renal disease. A major issue in the
management of PUV is prenatal prediction of postnatal renal function. Fetal ultrasound and fetal urine biochemistry are
currently employed for this prediction, but clearly lack precision. We previously developed a fetal urine peptide signature
that predicted in utero with high precision postnatal renal function in fetuses with PUV. We describe here the objectives and
design of the prospective international multicentre ANTENATAL (multicentre validation of a fetal urine peptidome-based
classifier to predict postnatal renal function in posterior urethral valves) study, set up to validate this fetal urine peptide
signature.
Methods. Participants will be PUV pregnancies enrolled from 2017 to 2021 and followed up until 2023 in >30 European
centres endorsed and supported by European reference networks for rare urological disorders (ERN eUROGEN) and rare
kidney diseases (ERN ERKNet). The endpoint will be renal/patient survival at 2 years postnatally. Assuming a¼0.05,
1–b¼0.8 and a mean prevalence of severe renal outcome in PUV individuals of 0.35, 400 patients need to be enrolled to
validate the previously reported sensitivity and specificity of the peptide signature.
Results. In this largest multicentre study of antenatally detected PUV, we anticipate bringing a novel tool to the clinic. Based
on urinary peptides and potentially amended in the future with additional omics traits, this tool will be able to precisely
quantify postnatal renal survival in PUV pregnancies. The main limitation of the employed approach is the need for
specialized equipment.
Conclusions. Accurate risk assessment in the prenatal period should strongly improve the management of fetuses with
PUV.
Keywords: development, kidney disease, obstructive uropathy, prediction, prenatal biomarkers
INTRODUCTION
Posterior urethral valves (PUV) are a congenital anomaly asso-
ciated with a wide spectrum of outcomes ranging from
extremely severe phenotypes with prenatal death to live born
children with normal renal function. Exclusively found in
males, PUV is the major cause of severe obstructive nephropa-
thy in children. Although a rare disease (1 in 5000–8000 chil-
dren [1]), it accounts for 17% of paediatric end-stage renal
disease (ESRD) [2–4].
The management of PUV is hampered by the absence of
tools for adequate antenatal screening of PUV fetuses at a high
risk for developing ESRD. Current clinical practice is based on
prenatal ultrasound and fetal urine biochemistry, but this is
clearly insufficient to predict postnatal renal outcome with any
accuracy in PUV patients as shown in several (meta) studies [5–
7]. This lack of efficient prognostic methods leads to many
parents opting for termination of pregnancy (TOP) [6–8], and
also compromises adequate selection of fetuses that would po-
tentially benefit from prenatal intervention (vesicoamniotic
shunting or laser ablation of valves). Hence, new predictive
strategies are necessary to allow optimal diagnostic and thera-
peutic management of the disease.
In a small-scale proof-of-concept study, we recently identi-
fied a fetal urinary peptide signature that predicted in utero the
postnatal renal function of PUV fetuses with high accuracy [9],
outperforming routine ultrasound and fetal urine biochemistry.
These results sparked the interest of many obstetricians,
paediatric urologists and nephrologists in using this fetal signa-
ture in routine clinical care. On this background, we initiated
an international investigator-driven prospective large-scale
study, named ANTENATAL (clinicaltrials.gov NCT03116217;
‘multicentre vAlidatioN of a fetal urine pepTidome-based
classifiEr to predict postnatal reNAl function in posterior
ureThral vALves’), aiming to validate peptide signature in a
much larger multicentre setting. The ANTENATAL trial will en-
rol 400 PUV pregnancies screened in >30 European centres with
involvement of two large European Reference Networks on rare
diseases over a period of 4 years and with a patient follow-up
until the child’s age of 2 years. The ANTENATAL study will also
be an excellent opportunity to evaluate the potential of adding
other fetal urinary omics traits to peptide markers for kidney
disease stratification, including proteins, metabolites and
miRNAs, as we suggested in a recent study [10]. In addition, the
ANTENATAL trial will allow exploration of the possibility of
extending the omics analysis to amniotic fluid for a less
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invasive prediction of postnatal renal function in PUV pregnan-
cies. The present report introduces an overview, the design and
objectives of the ANTENATAL trial.
ANTENATAL RATIONAL
Body fluid peptide-based biomarker panels display clear prom-
ise for the management of kidney disease because of their im-
proved efficacy over single markers and the relative proximity
of peptides to the phenotype compared with other omics traits
[11, 12]. In the first attempt to show that peptides present in fe-
tal urine could serve as biomarkers to predict postnatal renal
function in PUV fetuses, we prospectively recruited 66 PUV
patients from 26 different French centres. Using 28 PUV fetuses,
we identified 26 fetal urinary peptides strongly associated with
postnatal renal survival [9]. Twelve of those were combined in a
signature that we called the ‘12PUV classifier’. This signature
showed excellent performance in predicting the postnatal onset
of early ESRD in the 38 blindly assessed additional PUV fetuses
with a sensitivity of 88% [95% confidence interval (95% CI)
66–98%], a specificity of 95% (95% CI 80–100%) and an area
under the receiver operator characteristic curve (AUC) of 0.94
(95% CI 0.82–0.99) (Figure 1A). The predictive efficacy of the
12PUV classifier was compared with routine clinical parame-
ters, including ultrasound-measured characteristics of the
fetal kidneys (hyperechogenicity, dysplasia, presence of cysts or
aspect of renal cortex) and amniotic fluid volume (oligohydram-
nios or anhydramnios) as well as fetal urine biochemistry
[sodium, b2-microglobulin (b2M)]. Based on accuracy (Figure 1B),
the 12PUV classifier correctly classified 35/38 patients [92% (95%
CI 84–100%)] compared with the best ultrasound (multicystic
dysplastic kidneys) and biochemical (b2M) parameters, which
correctly predicted 27/38 [71% (95% CI 57–85%)] and 26/38
patients [68% (95% CI 54–83%)], respectively. This clearly dem-
onstrating that the 12PUV classifier outperformed the conven-
tional approaches.
ANTENATAL OBJECTIVES
The primary objective of the ANTENATAL study is to prospec-
tively validate the use of the fetal urine peptidome-based 12PUV
classifier [9] to predict in utero postnatal renal function in
fetuses with PUV in a large international multicentre cohort.
The secondary objectives are to: (i) evaluate whether adding
additional omics traits (miRNAs, proteins and metabolites) to
the 12 peptide markers further improves the stratification;
(ii) explore the predictive biomarker content of amniotic fluid as
a less invasive biological fluid; (iii) compare the predictive effi-
cacy of the 12PUV classifier for renal/patient survival at 2 years
postnatally with conventional methods (fetal ultrasound and
urine biochemistry); (iv) assess whether the accuracy of the
12PUV-mediated prediction is modified by intervention (e.g.
vesico amniotic shunting or laser cystoscopy ablation of the
valves according to local clinical practice); (v) determine the
stability and reproducibility of the 12PUV-mediated prediction
if multiple sequential fetal urine samples of a patient are
FIGURE 1: Performance of a panel of 12 fetal urinary peptides (12PUV classifier) in predicting postnatal renal outcome in fetuses with PUV (proof of concept study).
(A) Receiver operator characteristic curve for prediction of postnatal renal survival using the 12PUV classifier (38 fetuses, 16 with early ESRD, 22 without ESRD at 2 years
postnatally). Adapted from Klein et al. [9] with permission. (B) Predictive accuracy of the 12PUV classifier compared with the clinical parameters
including routinely ultrasound-measured characteristics of the fetal kidneys and amniotic fluid volume (oligoamnios or anhydramnios) as well as fetal urine biochem-
istry. *P < 0.05, **P < 0.01, ***P < 0.001 versus the 12PUV classifier using the McNemar test for paired proportions. Adapted from Klein et al. [9] with permission.
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available; and (vi) have a standardized collection of pre- and
postnatal clinical and demographic data on the outcome of
PUV pregnancies.
ANTENATAL IMPLEMENTATION
Design, participants and setting
ANTENATAL is an international multicentre prospective case
study designed to validate the performance of the 12PUV classi-
fier for in utero prediction of the postnatal renal outcome of PUV
fetuses. ANTENATAL anticipates to enrol 400 PUV pregnancies
in >30 multidisciplinary prenatal diagnosis centres in nine
European countries (Belgium, France, Germany, Italy, Poland,
Spain, The Netherlands, Switzerland and Sweden). Inclusion
started in June 2017 and plans to end, under optimal conditions,
in June 2021, while follow-up will continue up to December
2023. Eligible patients are mothers carrying male singleton fetus
with suspected PUV according to the following inclusion
criteria: (i) detection of a megabladder associated with urinary
tract anomalies with or without dysplastic or hyperechogenic
parenchyma in a first ultrasound; (ii) confirmation of
megabladder in the second ultrasound; (iii) collection of fetal
urine taken during the routine management of the disease for
biochemistry evaluation; and (iv) signature of a written in-
formed consent. Non-inclusion criteria are: (i) persons protected
by law and (ii) refusal to participate in the study. The exclusion
criteria include: (i) patients lost in follow-up, leaving the study
or withdrawing consent; (ii) detection of major structural or
chromosomal anomalies in karyotype; and (iii) lack of PUV con-
firmation in the postnatal period or by anatomo-pathological
analysis in case of pregnancy termination or neonatal death.
The setup of the ANTENATAL study is reported in Figure 2.
Ethical aspects
The ANTENATAL study (clinicaltrials.gov NCT03116217, started
on 26 June 2017) was approved by the national ethics committee
for the coordinating centre (No. RCB2016-A01914-47, France).
The study is carried out in accordance with the ethical princi-
ples expressed in the Declaration of Helsinki. In particular,
appropriate written informed consent for fetal urine sampling
and laboratory testing will be obtained from all parents of
fetuses participating in the study, as previously indicated in the
inclusion criteria.
FIGURE 2: ANTENATAL study setup. Four hundred patients recruited in >30 centres will enter the ANTENATAL study with a confirmed presence of a megabladder in
the prenatal period. Fetal urine and/or amniotic fluid will be sampled. Fetal urine will be scored with the previously identified peptide-based 12PUV classifier and then
compared with renal outcome at 2 years, and renal function at a number of time-points after birth. Fetal urine content in additional omics traits, including proteins,
miRNAs and metabolites, will be explored to determine the added value of combining those traits with the peptide-based 12PUV classifier. Amniotic fluid samples
will be screened for omics biomarkers of postnatal function in PUV to eventually move the analysis into a less invasive body fluid. Follow-up of all patients will be
performed according to local standard care, which can be with or without intervention (vesicoamniotic shunt/laser ablation of valves).
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Outcomes
The primary judgment criterion (endpoint) is renal/patient
survival at 2 years postnatally, defined by the need for dialysis
or death. The secondary judgment criterion is renal function of
the live born at 1 month, 6 months and 1 year postnatally.
Procedure and assessment
Study organization. The study organization has been schema-
tized in Figure 3. An in-house-developed electronic case report
form (eCRF, Supplementary data) has been established.
According to local clinical practice to limit additional burden
on the patients, fetal urine, amniotic fluid (if still present in a cer-
tain amount) and postnatal urine samples, as well as pre- and
post-clinical data, will be collected. Clinical data can be anony-
mously entered in the centralized eCRF at any time during
follow-up. It is anticipated that recruitment will last for 4 years to
reach the 400 patients to be screened. An additional follow-up pe-
riod of at least 2 years will be required to obtain endpoint data for
the last included patients. This period is paralleled by fetal uri-
nary peptidome analysis and initiation of the analysis of addi-
tional omics traits in both fetal urine and amniotic fluid.
Routine monitoring. Prenatal visits (Table 1) aim to obtain a set
of ultrasound-measured parameters of kidneys and urinary
tract of PUV fetuses. A minimum of one prenatal visit is re-
quired and optimally data from four prenatal visits are
expected. This will provide information on the antenatal evolu-
tion of the disease and will allow comparison of the efficacy of
the omics-based prognosis tools with the routine clinical
parameters. Postnatal visits (Table 1) are scheduled to perform
anthropometric examination, postnatal biochemistry, and kid-
ney and urinary tract ultrasound. The first postnatal visit fur-
ther aims to confirm the presence of PUV (or confirm the correct
removal of the valves in case of prenatal laser intervention); it
will also serve to record the outcome of the pregnancy. In case
of TOP or neonatal death, a standardized anatomo-pathological
analysis will be proposed to the parents for the determination
of the severity of renal lesions (oligomeganephronia, dysplasia,
presence of immature glomeruli and tubules). The final visit
includes recording of documentation of surgery, any postnatal
complications, admissions to the hospital, number of urinary
tract infections and medication during the first 2 years of life.
Four postnatal visits are ideally planned during the 2-year post-
natal follow-up, the minimum being one visit. The end of study
visit equals the 24-month visit (M24), except for TOP or neonatal
death, where the last visit will serve as the end of study visit.
Biosamples and omics analysis. Details can be found in
Supplementary data.
Statistics
To reach the primary objective, which is the validation of the fetal
urine peptidome-based 12PUV classifier to predict in utero postna-
tal renal function in fetuses with PUV, we need to confirm its
both sensitivity (88%) and specificity (95%). The 12PUV classifier
comprises a scoring scheme, which includes positive and nega-
tive predictive values (PPV and NPV, respectively). Power and
sample size calculation for this specific setting and the validation
of both PPV and NPV have been addressed by Steinberg et al., de-
veloped especially for this type of diagnostic tests [13]. Hence,
according to Steinberg’s method, focusing on the test’s specificity
without compromising sensitivity, using a range of prevalence of
ESRD in PUV individuals from 0.24–0.45 (mean: 0.35) [14, 15] and
assuming a¼ 0.05 (significance level) and 1  b¼ 0.8 (power), we
calculated that the sample size estimation to reach the primary
objective is 400 patients to be enrolled.
DISCUSSION
It is essential to confirm that any developed diagnostic or prog-
nostic method also predicts well in, and thus is generalizable to,
FIGURE 3: ANTENATAL study flow chart. The inclusion period will last for 48 months. The participation of each patient will carry on for 30 months, thereby resulting
in a total duration of 78 months for the ANTENATAL trial.
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‘similar but different’ individuals outside the setting in which
the method was developed [16]. The ANTENATAL trial is
expected to validate the previously identified 12PUV classifier
[9] in the first and the largest prospective cohort focusing on
fetuses with PUV. Here, validation will be simultaneously tem-
poral and geographical, since some new patients will be
recruited in the same institutions (France) as in the develop-
ment sample, but at a later point in time, while other patients
will be enrolled from eight additional countries. On 1 July 2019,
the eCRF contained 55 patient entries from 15 different centres.
Since PUV is a rare disorder, international collaboration
is necessary to obtain data from the patients needed for this
study. The European Reference Networks (ERNs) were estab-
lished to tackle rare conditions by bringing together healthcare
providers across Europe. ANTENATAL is an international study
that was initiated before the start of the ERNs, but after their
acceptance, we approached both the centres participating in
the European Rare Kidney Diseases Reference Network (ERN
ERKNet, www.erknet.org; 31 July 2019, date last accessed) and
the centres participating in the Rare Urogenital Diseases
Network (ERN eUROGEN, http://eurogen-ern.eu/; 31 July 2019,
date last accessed). This led to additional centres including
patients for ANTENATAL, and endorsement of the ANTENATAL
study by those two ERNs.
Collaboration was also established with the Radboudumc
Aetiologic research into Genetic and Occupational/
Environmental Risk Factors for Anomalies in Children
(AGORA) data and biobank [17]. AGORA currently contains
data of 500 PUV patients. To further enrich this resource,
we asked the ANTENATAL centres to collect DNA samples of
children and their parents and parental questionnaires on a
range of non-genetic risk factors for AGORA. This collabora-
tion allows the AGORA researchers to include more patients,
and allows us to also evaluate the added value of genomic
biomarkers.
With 88% sensitivity and 95% specificity shown in the proof-
of-concept study [9], we anticipate that the 12PUV classifier will
display superiority over conventional methods in predicting
postnatal renal outcome. Beyond its best predictive accuracy,
this fetal urine peptide-based tool will have the double benefit
of being objective and quantifiable. Indeed, the measurement of
fetal urine peptides is not subjected to personal interpretation,
as can be the case for sonographic imaging. In addition, the
recent and fast evolution of techniques for the analysis of
the molecular content of biological fluids opens the possibility
of studying additional molecular levels, including miRNAs,
proteins and metabolites. As demonstrated recently [10], the
combination of fetal urinary peptide and metabolite markers
extracted from the same sample generated a clear added value
with respect to metabolites alone for the prediction of progres-
sion of PUV disease.
In addition to fetal urine, omics analysis in amniotic fluid dis-
plays promise for the clinic, since it has emerged as a reliable
source of biomarkers for fetal diseases [18, 19]. In this context, we
recently identified a novel amniotic fluid peptide signature that
predicts postnatal renal function in bilateral congenital anoma-
lies of kidney and urinary tract, including but not limited to PUV,
thereby potentially strongly improving the prenatal diagnostic
workup of the disease (clinicaltrials.gov NCT02675686, 178
fetuses, unpublished results). Hence, the expansion of biomarker
research to amniotic fluid in the ANTENATAL project opens the
possibility of predicting postnatal renal function in fetuses with
PUV using a less invasive sample. Of note, the omics analysis of
markers of PUV severity can most likely not be extended to
maternal plasma or urine even if such body fluids are easier to
collect than amniotic fluid [18]. Furthermore, it appears that the
risk of miscarriage and stillbirth in women undergoing amnio-
centesis is mostly increased in high-risk pregnancies [20, 21].
Announcement of anomalies such as PUV is a traumatic and
emotive event for families anticipating an unsecured long-term
health outcome for their future newborn. In addition, the lim-
ited value of ultrasound-based analysis and fetal urinary bio-
chemistry in predicting postnatal ESRD led in the past to
unnecessary fetal interventions, TOPs, sometimes contradicted
by fetopathology, or continuation of pregnancies resulting in
early ESRD [5–8]. The introduction of an ANTENATAL-validated
prognostic panel of fetal urinary peptides in the prenatal care
of patients with PUV can guide clinicians in the counselling
process by delivering unbiased and unambiguous prognostic in-
formation. This will improve disease management in many
ways, impacting both affected patients and their family by:
(i) reducing stress of parents related to the uncertainty of well-
being of their unborn infant; (ii) alleviating the enormous psy-
chological burden of parents associated with their decision
to continue or terminate pregnancy; (iii) potentially avoiding
unnecessary interventions, stressful for the mother and risky
even if performed by fetoscopic surgery; (iv) potentially avoiding
unnecessary pregnancy termination; and (v) anticipating renal
replacement therapy or palliative care of newborns if continua-
tion of the pregnancy is decided in fetuses predicted in the
high-risk stratum.
SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
ACKNOWLEDGEMENTS
We would like to thank Nadège Algans (Direction de la
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Debromez, Jérôme Harembat and Brigitte Llanas, CHU
The ANTENATAL study announcement | 377
Pellegrin 33078 Bordeaux, France; Romain Favre, Raphael
Moog and Ariane Zaloszyc, SIHCUS-CMCO 67300
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